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Abstract We examined risk factors for advanced hepatic
fibrosis [fibrosis-4 (FIB)-4[3.25] including both current
alcohol use and a diagnosis of alcohol use disorder among
HIV-infected patients. Of the 12,849 patients in our study,
2133 (17%) reported current hazardous drinking by
AUDIT-C, 2321 (18%) had a diagnosis of alcohol use
disorder, 2376 (18%) were co-infected with chronic hep-
atitis C virus (HCV); 596 (5%) had high FIB-4
scores[3.25 as did 364 (15%) of HIV/HCV coinfected
patients. In multivariable analysis, HCV (adjusted odds
ratio (aOR) 6.3, 95% confidence interval (CI) 5.2–7.5),
chronic hepatitis B (aOR 2.0, 95% CI 1.5–2.8), diabetes
(aOR 2.3, 95% CI 1.8–2.9), current CD4\200 cells/mm3
(aOR 5.4, 95% CI 4.2–6.9) and HIV RNA[500 copies/mL
(aOR 1.3, 95% CI 1.0–1.6) were significantly associated
with advanced fibrosis. A diagnosis of an alcohol use dis-
order (aOR 1.9, 95% CI 1.6–2.3) rather than report of
current hazardous alcohol use was associated with high
FIB-4. However, among HIV/HCV coinfected patients,
both current hazardous drinkers (aOR 1.6, 95% CI 1.1–2.4)
and current non-drinkers (aOR 1.6, 95% CI 1.2–2.0) were
more likely than non-hazardous drinkers to have high FIB-
4, with the latter potentially reflecting the impact of sick
abstainers. These findings highlight the importance of
using a longitudinal measure of alcohol exposure when
evaluating the impact of alcohol on liver disease and
associated outcomes.
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Introduction
Decompensated liver disease has been a major cause of
non-AIDS-related death among HIV-infected persons since
the advent of combination antiretroviral therapy [1]. While
the contribution of chronic viral hepatitis to liver-related
morbidity and mortality has been well established [1, 2],
less is known about the impact of alcohol use on liver
disease progression, relative to other known risk factors
such as viral hepatitis or immune suppression in HIV-in-
fected patients [3]. Variability in definitions of alcohol use,
outcome measurement and study populations in previous
reports may have contributed to inconsistent findings [4–7].
Understanding the relative influence of alcohol use, both
current and historical, on the natural history of liver disease
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is essential given that it remains one of the more prevalent
modifiable factors.
Due to the invasive nature and limitations of biopsy [8],
noninvasive markers have been useful in determining
advanced fibrosis in population-based studies. The fibrosis-
4 (FIB-4) index, derived from age, liver aminotransferases
and platelet count, is more widely available than biopsy,
and has been shown to predict liver-related events and
death in patients with chronic hepatitis C virus infection
(HCV), HIV and HIV/HCV co-infection [9–12].
In a large cohort of HIV-infected patients receiving care
across the US, we sought to define the impact of current
and historical alcohol use on hepatic fibrosis as measured
by FIB-4 in the context of other comorbidities including
viral hepatitis, diabetes and HIV disease markers.
Accounting for other factors, we examined the effect of
current alcohol use, measured systematically across sites
using standardized clinical assessments, as well as a clin-
ician-documented diagnosis of an alcohol use disorder on
the development of advanced hepatic fibrosis.
Methods
The Centers for AIDS Research (CFAR) Network of
Integrated Clinical Systems (CNICS) data repository cap-
tures comprehensive clinical data that include standardized
diagnosis, medication, laboratory, and demographic infor-
mation collected through electronic medical records and
other institutional data systems at each site [13]. Data are
updated quarterly and undergo extensive quality assurance
procedures prior to data transmission, at the time of sub-
mission, and during integration into the CNICS repository
(http://www.uab.edu/cnics). Additionally, patients com-
plete standardized clinical assessments as part of routine
clinical care that include questions on adherence and sub-
stance use in English or Spanish using touch-screen tablets
[14]. We conducted a cross-sectional study at seven clinical
sites in the CNICS cohort among all patients who com-
pleted at least one clinical assessment from September
2005 to September 2015 and had at least one set of labo-
ratory measurements available to calculate FIB-4. Institu-
tional review boards at each site approved the study
protocol.
Current alcohol use was assessed using the alcohol use
disorders identification test-consumption (AUDIT-C)
questionnaire [15]. The AUDIT-C is collected as part of
self-administered standardized clinical assessments which
were introduced into routine care at CNICS sites at varying
time points between 2007 and 2015. For the main analysis,
we used data from the most recent clinical assessment for
each patient. We defined current hazardous drinking as an
AUDIT-C score C5 for men, C4 for women and
categorized patients into current non-drinkers, non-haz-
ardous drinkers and hazardous drinkers [16]. Patients who
had a diagnosis of alcohol abuse or dependence recorded
by the treating clinician any time prior to the assessment
date were classified as having an alcohol use disorder using
a modified list of International Classification of Diseases,
Ninth Revision diagnostic codes (291.x, 303.x and 305.0),
which have been shown to be moderately sensitive and
highly specific for alcohol use disorders (AUD) [17, 18].
The period of observation over which individuals could
have an AUD diagnosis assigned was a median of 6 years
and median of 23 encounters (5 and 85 encounters for 5th
and 95th percentiles). We defined chronic HCV infection
as ever having detectable HCV RNA or positive HCV
antibody test and chronic hepatitis B (HBV) as the pres-
ence of detectable HBV DNA or positive HBV surface
antigen before the assessment. Diabetes mellitus was
defined as a diagnosis of diabetes mellitus recorded by the
treating clinician and use of diabetes-related medication, or
use of diabetes-specific medication, or a hemoglobin
A1C C6.5% [19]. Body mass index (BMI) was defined as
underweight (\18.5 kg/m2), normal range (18.5 to\25 kg/
m2), overweight (25–29 kg/m2) and obese (C30 kg/m2).
Current CD4 cell count and plasma HIV RNA level [‘‘viral
load’’ (VL)] were the values closest to the date of the
assessment. CD4 count was categorized as C500,
200–499,\200 cells/mm3. Undetectable (VL\500 copies/
mL) versus detectable VL was a measure of effective ART.
We computed FIB-4 index according to the formula:
(age [years] 9 AST [IU/L])/(platelets [109/L] 9 (ALT
[IU/L])1/2) [20] using the ALT, AST and platelet count
closest to the assessment date. We defined high FIB-4 as a
score exceeding 3.25, a threshold validated in other settings
and predictive not only of advanced fibrosis, but of liver-
related outcomes and overall mortality [9–11, 20–22].
We used v2 tests to examine bivariate associations and
multivariable logistic regression to determine factors
associated with advanced fibrosis by FIB-4 including
chronic HCV, chronic HBV, current alcohol use, diagnosis
of alcohol use disorder, diabetes, current CD4 count, cur-
rent VL, sex and race. We did not include risk factor for
HIV transmission in the model because of collinearity
between injection drug use (IDU) and HCV, nor age as a
separate variable because it is a component of the FIB-4
index. BMI was not associated with FIB-4 and therefore
omitted from the final model. We explored the possibility
of effect modification of HCV status on FIB-4 by alcohol
by (1) performing the analysis using different levels of
alcohol use and (2) including an interaction term in the
model. We evaluated our model stratified by HCV status
and conducted sensitivity analyses that evaluated the
maximum AUDIT-C score across multiple measurements
per individual if more than one assessment was available.
count\200 cells/mm3, and 84% had a current VL\500
copies/mL (Table 1). The study cohort was similar in
baseline characteristics (age, sex, race, HCV co-infection
and AUD) to the overall cohort.
Of these, 3459 patients (27%) had FIB-4 indices[1.45
indicative of at least moderate fibrosis [20] and 596 (5%) had
a high FIB-4 score[3.25 indicating advanced fibrosis. The
majority (61%) of patients with high FIB-4 were HCV co-
infected; 12% were HBV co-infected, 21% had diabetes
mellitus, and 39% had a diagnosis of an alcohol use disorder.
Thirty-six percent of the study population identified
themselves as current non-drinkers, 47% as current non-
hazardous drinkers, and 17% as current hazardous drinkers
Table 1 Demographic and
clinical characteristics of the
study population
Total (N = 12,849) Low FIB-4a (n = 12,253) High FIB-4a (n = 596)
Age, years (median, IQR) 47 (38–51) 45 (37–51) 53 (47–58)
Sex, male 10,698 (83) 10,216 (83) 482 (81)
Race
White 6049 (47) 5789 (47) 260 (44)
Black 4475 (35) 4227 (35) 248 (42)
Hispanic 1721 (13) 1655 (14) 66 (11)
Other 604 (5) 582 (5) 22 (4)
HIV risk factor
MSM 7460 (58) 7238 (59) 222 (37)
IDU 2070 (16) 1832 (15) 238 (40)
Heterosexual 2926 (23) 2819 (23) 107 (18)
Other 393 (3) 364 (3) 29 (5)
Chronic hepatitis C 2376 (18) 2012 (16) 364 (61)
Chronic hepatitis B 716 (6) 646 (5) 70 (12)
Diabetes mellitus 1308 (10) 1183 (10) 125 (21)
Current CD4 count (cells/mm3)
C500 6971 (54) 6819 (56) 152 (25)
200–499 4468 (35) 4212 (34) 256 (43)
\200 1410 (11) 1222 (10) 188 (32)
Current HIV RNA levelb
\500 copies/mL 10,820 (84) 10,389 (85) 431 (72)
Current ARTc 11,435 (89) 10,920 (89) 515 (86)
Alcohol use disorder 2321 (18) 2091 (17) 230 (39)
Current alcohol used
No drinking 4637 (36) 4338 (35) 299 (50)
Non-hazardous 6079 (47) 5882 (48) 197 (33)
Hazardous 2133 (17) 2033 (17) 100 (17)
Values represent number (%) except for the category age
IQR interquartile range, MSM men who have sex with men, IDU injection drug use, ART antiretroviral
therapy
a FIB-4 index[3.25 represented high FIB-4. P-values were\0.005 for all comparisons between high and
low FIB-4 groups except for sex (p = 0.11) and current ART (p = 0.04)
b Lab value closest to clinical assessment
c As reported in the clinical assessment
d Non-hazardous: AUDIT-C score\5 for men,\4 for women. Hazardous: AUDIT-C score C5 for
men, C4 for women
All analyses were performed using Stata 14 (College Sta-
tion, TX).
Results
Of the 13,386 patients in care from September 2005 to 
September 2015 at the seven CNICS sites that participated 
in clinical assessments, 12,849 individuals completed at 
least one assessment and had at least one set of lab mea-
surements available to compute FIB-4. Study subjects were 
mostly men (83%) with a median age of 47 years, 47%
were white, 35% were black, 11% had a current CD4
by AUDIT-C scores. Eighteen percent of patients had a
diagnosis of an alcohol use disorder with a greater pro-
portion among HCV co-infected than HIV mono-infected
patients (32 vs. 15%, p\ 0.001). Current hazardous
drinking was more prevalent among patients with a diag-
nosis of alcohol use disorder than those without (30 vs.
14%, p\ 0.001). However, patients with chronic HCV
were more likely to report that they were currently not
drinking than those without HCV (51 vs. 33%, p\ 0.001).
In bivariate analysis, black race, chronic HCV, chronic
HBV, diabetes, current CD4 count and current VL were
associated with high FIB-4 while sex was not. Patients with
a diagnosis of an alcohol use disorder were significantly
more likely to have advanced fibrosis than those without a
diagnosis (9.9 vs. 3.5%, p\ 0.001). There was no differ-
ence in the proportion of patients with high FIB-4 among
those who reported current hazardous drinking compared
with those who did not (4.7 vs. 4.6%, p = 0.90). However,
when we evaluated current alcohol use separating non-
drinkers from non-hazardous drinkers, non-drinkers had
just over twofold greater odds (p\ 0.001) and hazardous
drinkers a 1.5-fold greater odds (p = 0.002) compared with
non-hazardous drinkers for high FIB-4. Notably, the rela-
tionship between FIB-4 and AUDIT-C examined as a
continuous variable was not linear, but demonstrated a
J-curve reflecting higher risk among current non-drinkers
compared with non-hazardous drinkers for elevated FIB-4.
The prevalence of alcohol use disorder (19 vs. 13%,
p\ 0.001) and HCV infection (26 vs. 14%, p\ 0.001)
was greater among non-drinkers compared with non-haz-
ardous drinkers highlighting the subset of current non-
drinkers who had a prior history of extensive alcohol use
and then stopped drinking.
In a multivariable model that included sex, race and both
current alcohol use as well as an alcohol diagnosis among
the overall study cohort (Table 2), we found that HCV
infection (adjusted odds ratio [aOR] 6.3, 95% confidence
interval [CI] 5.2–7.5), HBV infection (aOR 2.0, 95% CI
1.5–2.8), diabetes (aOR 2.3, 95% CI 1.8–2.9), current
CD4\200 cells/mm3 (aOR 5.4, 95% CI 4.2–6.9) and
current VL[500 copies/mL (aOR 1.3, 95% CI 1.0–1.6)
were significantly associated with advanced fibrosis by
FIB-4. In addition, a diagnosis of an alcohol use disorder
was independently associated with high FIB-4 (aOR 1.9,
95% CI 1.6–2.3).
Current hazardous alcohol use compared with non-haz-
ardous use was not associated with high FIB-4, but current
non-drinking was independently associated with elevated
FIB-4 in the overall cohort (aOR 1.3, 95% CI 1.1–1.6).
However, when we stratified our model by HCV status
(Table 3), neither current non-drinking nor current hazardous
drinking were associated with high FIB-4 in HIV mono-in-
fected patients while all of the aforementioned factors
remained independently associated with high FIB-4 with the
Table 2 Factors associated
with advanced liver fibrosis by
FIB-4[3.25
Factor Bivariate analysis Multivariable analysis
OR 95% CI p Value aOR 95% CI p Value
Male sex 0.8 0.7–1.0 0.11 1.0 0.8–1.3 0.70
Race (ref: white)
Black 1.3 1.1–1.6 0.003 0.9 0.7–1.1 0.36
Other 0.9 0.7–1.1 0.29 0.9 0.7–1.1 0.23
Chronic hepatitis C 8.0 6.7–9.5 \0.001 6.3 5.2–7.5 \0.001
Chronic hepatitis B 2.4 1.8–3.1 \0.001 2.0 1.5–2.8 \0.001
Diabetes mellitus 2.5 2.0–3.1 \0.001 2.3 1.8–2.9 \0.001
Alcohol use disorder 3.1 2.6–3.6 \0.001 1.9 1.6–2.3 \0.001
Current alcohol usea (ref: non-hazardous)
No drinking 2.1 1.7–2.5 \0.001 1.3 1.1–1.6 0.006
Hazardous 1.5 1.1–1.9 0.002 1.3 0.9–1.6 0.09
Current CD4 countb, cells/mm3 (ref: C500)
200–499 2.7 2.2–3.3 \0.001 2.4 1.9–3.0 \0.001
\200 6.9 5.5–8.6 \0.001 5.4 4.2–6.9 \0.001
Current HIV viral loadb, copies/mL (ref:\500)
C500 2.1 1.8–2.6 \0.001 1.3 1.0–1.6 0.02
OR odds ratio, aOR adjusted odds ratio, CI confidence interval
a Non-hazardous: AUDIT-C score\5 for men,\4 for women. Hazardous: AUDIT-C score C5 for
men, C4 for women
b Closest to assessment date
39% had a diagnosis of alcohol use disorder. Past and
current alcohol use was prevalent in our cohort. A diag-
nosis of alcohol use disorder was independently associated
with advanced hepatic fibrosis among both HIV-monoin-
fected and HIV/HCV coinfected patients. However current
hazardous alcohol use was not associated with high FIB-4
in the overall cohort, even when we evaluated all available
AUDIT-C scores. We found the association of current
hazardous use and high FIB-4 only in HIV/HCV coinfected
patients but not when all available AUDIT-C values were
accounted for, suggesting that the link between the most
recent FIB-4 elevation and current hazardous drinking may
reflect acute, transient alcohol-related injury rather than
hepatic fibrosis per se. Notably, neither alcohol use disor-
der nor current alcohol use appeared to modify the effect of
HCV on FIB-4.
While assessment of current alcohol use remains
important in clinical care, our findings suggest that a
diagnosis of an alcohol use disorder, which appears to
capture more prolonged and severe exposure, may be a
more specific marker for the cumulative use of alcohol
harmful enough to promote hepatic fibrosis. Our findings
suggest that we should go beyond a ‘‘snapshot’’ assessment
of alcohol use and strive for a longitudinal or cumulative
measure of alcohol exposure when evaluating patients and
their risk of hepatic fibrosis. Indeed, HIV/HCV coinfected
patients who were current non-drinkers appeared to have a
greater risk of advanced fibrosis compared with current
Table 3 Factors associated




Factor HIV-monoinfected (n = 10,473) HIV/HCV coinfected (n = 2376)
aOR 95% CI p Value aOR 95% CI p Value
Male sex 0.9 0.6–1.3 0.57 1.1 0.8–1.5 0.42
Race (ref: white)
Black 0.7 0.5–0.9 0.018 1.1 0.8–1.4 0.56
Other 0.7 0.5–1.0 0.034 1.1 0.8–1.6 0.60
Chronic hepatitis B 3.0 2.0–4.4 \0.001 1.3 0.8–2.0 0.29
Diabetes mellitus 2.2 1.5–3.2 \0.001 2.3 1.7–3.1 \0.001
Alcohol use disorder 2.1 1.5–2.8 \0.001 1.8 1.4–2.3 \0.001
Current alcohol usea (ref: non-hazardous)
No drinking 1.1 0.8–1.5 0.50 1.6 1.2–2.0 0.002
Hazardous 1.0 0.7–1.4 0.92 1.6 1.1–2.4 0.01
Current CD4 countb, cells/mm3 (ref: C500)
200–499 3.2 2.2–4.6 \0.001 2.0 1.5–2.6 \0.001
\200 8.4 5.7–12.2 \0.001 3.8 2.7–5.3 \0.001
Current HIV viral loadb, copies/mL (ref:\500)
C500 1.5 1.1–2.0 0.01 1.1 0.8–1.5 0.49
aOR adjusted odds ratio, CI confidence interval
a Non-hazardous: AUDIT-C score\5 for men,\4 for women. Hazardous: AUDIT-C score C5 for
men, C4 for women
b Closest to assessment date
exception of black race (aOR 0.7, 95% CI 0.5–0.9). In con-
trast, among HIV/HCV coinfected patients, both non-drin-
kers and hazardous drinkers had a greater risk of high FIB-4 
(aOR 1.6, 95% CI 1.2–2.0 and aOR 1.6, 95% CI 1.1–2.4 
respectively). There was no association between FIB-4 and 
hepatitis B or HIV VL among coinfected patients possibly 
due to fewer individuals in those categories. Neither a history 
of an alcohol use disorder nor current alcohol use modified 
the effect of chronic HCV on FIB-4 (data not shown).
In sensitivity analyses, we examined all available 
AUDIT-C scores (69% of our cohort had at least two or more 
clinical assessments although 67% of these occurred during 
B2 years of follow-up) using the maximum AUDIT-C score, 
and again found no association between FIB-4 and current 
hazardous alcohol use as compared with non-hazardous use, 
and this lack of association was seen even among HIV-HCV 
coinfected patients. Current non-drinking and all other 
covariates remained independently associated with high 
FIB-4 including alcohol use disorder (data not shown).
Discussion
In our contemporary multi-site study of 12,849 HIV-in-
fected patients in routine care, 596 (5%) had a high FIB-4
score [3.25 indicating advanced fibrosis. Over half (61%) 
of patients with high FIB-4 were HCV co-infected; 12%
were HBV co-infected, 21% had diabetes mellitus, and
non-hazardous drinkers. Others have shown a higher risk of
adverse health outcomes in alcohol abstainers compared to
light-to-moderate drinkers in the general population [23] as
well as among people living with HIV [24]. To our
knowledge, our study is the first to demonstrate in HIV/
HCV coinfected individuals that current non-drinkers may
be at greater risk for advanced fibrosis. These findings
suggest a ‘‘sick quitter’’ phenomenon where a key subset of
abstainers are not lifetime abstainers but former heavy
drinkers [25] or those who quit for health reasons, which
was certainly supported by the higher prevalence of alcohol
use disorder and HCV infection among current non-drin-
kers compared with non-hazardous users in our cohort. A
diagnosis of alcohol use disorder, however, is likely only
the ‘‘tip of the iceberg’’ when used as a cumulative measure
of alcohol use.
Alcohol use disorder was prevalent among HCV co-
infected patients but this group reported current hazardous
drinking less frequently than mono-infected patients. This
finding may reflect a reluctance to disclose hazardous
drinking or the impact of screening and much greater focus
on counseling regarding the impact of alcohol in this at-risk
population. Nearly half (49%) of HCV co-infected patients
reported that they were still drinking, underscoring the
importance of addressing alcohol use with patients so that
they can modify behavior [26].
After controlling for traditional risk factors such as
alcohol, viral hepatitis and diabetes, we found that
advanced fibrosis by FIB-4 was significantly associated
with detectable HIV VL and lower CD4 count, which have
been linked with greater risk of significant hepatic fibrosis
by transient elastography [4, 27] and liver decompensation
in HCV/HIV co-infected patients [22, 28]. This is consis-
tent with findings that antiretroviral therapy can reduce the
rate of fibrosis progression [29] and risk of liver-related
mortality in HIV/HCV co-infected patients [30].
Given the cross-sectional nature of our analysis, we
were unable to examine the temporal relationship between
these factors and the development of fibrosis. Healthcare
providers have been known to miss clinically significant
alcohol use, particularly in patients who lack evidence of
laboratory abnormalities [31], potentially introducing some
measurement bias, the possibility of reverse causality and
underestimation of alcohol use disorders. Current alcohol
use was self-reported, and may have been underreported
among patients with HCV infection and cirrhosis in whom
alcohol use is ill advised. Longitudinal analyses of AUDIT
C scores were not possible since most subjects had two or
fewer measures over a fairly limited timeframe. FIB-4
values can fluctuate due to comorbid conditions and acute
medical events but the sample size of our cohort and pre-
dominantly outpatient origin of these lab results likely
offset this variability. Despite these limitations, FIB-4 has
been shown to predict death [9–12] and liver decompen-
sation [22], and may surpass liver biopsy in this regard
[21].
Our study was conducted in a large, diverse cohort of
persons infected with HIV in the modern ART era with
systematic collection of current alcohol use using a well-
validated instrument. The size of our cohort allowed mul-
tiple comorbidities to be examined together to assess their
relative importance with respect to hepatic fibrosis, cap-
turing the clinical complexity of patients in real-world care
settings. Our findings underscore the importance of
addressing multiple modifiable factors, including alcohol
use, to prevent or slow the progression of liver disease in
HIV-infected individuals.
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